Evidence map›Paper›PMID 34326048›Full record

ArticleBMJ open2021

Treatment of tungiasis using a tea tree oil-based gel formulation: protocol for a randomised controlled proof-of-principle trial.

Solomon Abrha, Julia K Christenson, John McEwen, Wubshet Tesfaye, Susana Vaz Nery, Aileen Y Chang, Tim Spelman, Sam Kosari, Gabriel Kigen, Simon Carroll and 6 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 6 countries.

Solomon AbrhaPharmacy, Faculty of Health, University of Canberra, Canberra, Australian Capital Territory, Australia.
Julia K ChristensonPharmacy, Faculty of Health, University of Canberra, Canberra, Australian Capital Territory, Australia.
John McEwenPharmacy, Faculty of Health, University of Canberra, Canberra, Australian Capital Territory, Australia.
Wubshet TesfayePharmacy, Health Research Institute, University of Canberra, Canberra, Australian Capital Territory, Australia.ORCID 0000-0001-7208-2330
Susana Vaz NeryThe Public Health Interventions Research Program, The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, New South Wales, Australia.
Aileen Y ChangDepartment of Dermatology, University of California San Francisco, San Francisco, California, USA.
Tim SpelmanPublic Health, Burnet Institute International Health Research Group, Melbourne, Victoria, Australia.
Sam KosariPharmacy, Faculty of Health, University of Canberra, Canberra, Australian Capital Territory, Australia.
Gabriel KigenDepartment of Pharmacology and Toxicology, Moi University School of Medicine, Eldoret, Central, Kenya.
Simon CarrollPharmacy, Faculty of Health, University of Canberra, Canberra, Australian Capital Territory, Australia.
Jorg HeukelbachDepartment of Community Health, Federal University of Ceará, Fortaleza, Brazil, Fortaleza, Brazil.
Hermann FeldmeierInstitute of Microbiology and Infection Immunology, Campus Benjamin Franklin, Charité University Medicine, Berlin, Germany.
Andrew BartholomaeusDiamantina Institute, The University of Queensland, Woolloongabba, Queensland, Australia.
Mark DanielCentre for Research and Action in Public Health, Health Research Institute, University of Canberra, Canberra, Australian Capital Territory, Australia.
Gregory M PetersonSchool of Pharmacy, University of Tasmania, Hobart, Tasmania, Australia.ORCID 0000-0002-6764-3882
Jackson ThomasPharmacy, Faculty of Health, University of Canberra, Canberra, Australian Capital Territory, Australia Jackson.Thomas@canberra.edu.au.ORCID 0000-0002-0699-788X
University of Canberra · AUBurnet Institute · AUCharité - Universitätsmedizin Berlin · DEMoi University · KEThe University of Queensland · AUUniversidade Federal do Ceará · BRUniversity of California, San Francisco · USUniversity of Tasmania · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTungiasis (sand flea disease or jigger infestation) is a neglected tropical disease caused by penetration of female sand fleas, METHODS AND ANALYSIS: This trial is a randomised controlled trial (RCT) in primary schools (n=8) in South-Western Kenya. The study will include school children (n=88) aged 6-15 years with a confirmed diagnosis of tungiasis. The participants will be randomised in a 1:1 ratio to receive a 3-day two times a day treatment of either 5% TTO gel or 0.05% KMnO ETHICS AND DISSEMINATION: The trial protocol has been reviewed and approved by the University of Canberra Human Research Ethics Committee (HREC-2019-2114). The findings of the study will be presented at scientific conferences and published in a peer-reviewed journal. TRIAL REGISTRATION NUMBERS: Australian New Zealand Clinical Trials Registry (ACTRN12619001610123); PACTR202003651095100 and U1111-1243-2294.

Indexed as

Tea Tree OilTungiasisAustraliaCaribbean RegionChildFemaleHumansKenyaRandomized Controlled Trials as TopicTea Tree Oilcomplementary medicinedermatologyinfectious diseasesinfectious diseases & infestationspaediatric dermatology

Identifiers

PMID34326048
PMCPMC8323357
OpenAlexW3185254631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.